We have the chance to build an IP estate that goes hand in hand with our generic pharmaceutical strength and build proprietary biological platforms
The company has also launched Elyara, a portfolio of products in regenerative medical aesthetics focused on non-invasive skin and hair restoration
The company achieved 20% EBITDA profitability in Bengaluru and reached operational profitability across all its active cities
The investment will support the company’s plans to expand its network of specialised surgical hospitals across India.
The investment case for health technology in India is frequently overstated in one direction and understated in another
Subscribe To Our Newsletter & Stay Updated
